Medivir AB Release: Primary Efficacy and Safety Findings From Phase III Study of Simeprevir in Treatment-Experienced Patients Demonstrate Sustained Virologic Response

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global phase III PROMISE study. Results demonstrated that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir was administered once daily with pegylated interferon and ribavirin.

Help employers find you! Check out all the jobs and post your resume.

Back to news